摘要:
Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
摘要:
This invention provides a pharmaceutically acceptable salt of 5&agr;-pregn-16-en-3&bgr;-ol-20-one 3-sulfate ester, which is useful as a progestational agent.
摘要:
This invention provides non-immunosuppressive rapamycin dialdehydes, which are useful as neurotrophic agents, in the treatment of solid tumors, and vascular disease.
摘要:
This invention provides a pharmaceutically acceptable salt of 5.alpha.-pregn-16-3.beta.-ol-20-one 3-sulfate ester, which is useful as a progestational agent.
摘要:
Novel pharmaceutical compositions are comprised of the salt or ion pair formation of a non-steroidal anti-inflammatory drug and an antihistamine or other decongestant. The physico-chemical characteristics of these compositions show them to be substantially different from their parent acid or base and will enable the preparation of dual action sustained or enhanced relief therapy regimens. The compositions also possessed enhanced stability and therefore the multi-symptom relief can be incorporated into a number of dosage forms such as capsules, tablets, elixirs, ointments and the like.
摘要:
Improved oral formulations are prepared by admixing gemfibrozil with from 1 to 4%, by weight, of a pharmaceutically acceptable surfactant having an HLB value of from about 10 to about 50.
摘要:
The present invention is a stabilized enteric-coated pharmaceutical dosage form and processes for the preparation thereof. Dissolution stability after storage of the dosage form under high stress conditions is improved by an enteric-coated dosage form having an enteric coating wherein the coating is of the acrylic resin kind of from 14 mg/cm.sup.2 to 24 mg/cm.sup.2 or an enteric coating wherein the coating is of the acetate kind of from 14 mg/cm.sup.2 to 24 mg/cm.sup.2 and having a second coating of hydrophilic coating for example, hydroxypropyl cellulose, hydroxymethyl cellulose or hydroxypropylmethyl cellulose.
摘要翻译:本发明是一种稳定的肠溶包衣药物剂型及其制备方法。 通过具有肠溶衣的肠溶衣剂形式,其中所述涂层为14mg / cm 2至24mg / cm 2的丙烯酸树脂类型或肠溶衣,其中在高应激条件下储存剂型之后的溶解稳定性得到改善,其中 该涂层的醋酸盐类型为14mg / cm 2至24mg / cm 2,并且具有亲水涂层的第二涂层,例如羟丙基纤维素,羟甲基纤维素或羟丙基甲基纤维素。
摘要:
An orally administrable formulation of a biologically active, acid sensitive, proteinaceous agent comprises a composition of a lyophilized mixture of the proteinaceous agent and maltose, optionally with a particulate diluent. This composition is then uniformly coated with an alkaline-soluble polymeric film containing at least one partially esterified polymethacrylic acid as a major component.
摘要:
A water-dispersible formulation of gemfibrozil comprising finely divided particles of pure gemfibrozil uniformly coated with a mixture of a wax and at least one hydrophilic material, the coated particles in turn being overcoated with a minor amount of a surfactant.
摘要:
Certain derivatives of procaterol are believed to possess similar biological activity to the base compound, (i.e., as bronchodilators) but have greater stability and bioavailability.